Has Susan Ahern, DO received payments from drug or device companies?

Yes. Drug and device makers reported $1,040 in general payments to Susan Ahern, DO across 16 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Susan Ahern, DO did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Susan Ahern, DO come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Susan Ahern, DO

Endocrinology, Diabetes & Metabolism · Ventura, CANPI 1508156597

Payments from drug & device makers

$1,040in general payments, 2019–2025

Across 16 payments — averaging $64.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$712
Nevro Corp.$148
Dexcom, Inc.$116
Abbott$42
Sanofi-aventis U.S. LLC$21

What the payments were for

Food & beverage$92389%
Education$979%
Other$202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	11	$712
Nevro Corp.	1	$148
Dexcom, Inc.	1	$116
Abbott	2	$42
Sanofi-aventis U.S. LLC	1	$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,040 in reported general payments places this provider in the 45th percentile of 952 endocrinology, diabetes & metabolism providers in California.

See all endocrinology, diabetes & metabolism providers in California →

Medicare billing

Part B allowed, 2024

$417,096

Medicare patients

461

Services billed

20,166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
MounjaroTirzepatide	305	$478,544
OzempicSemaglutide	243	$423,308
JardianceEmpagliflozin	105	$132,428
RybelsusSemaglutide	34	$89,484
TrulicityDulaglutide	49	$84,062
WegovySemaglutide	29	$55,624
FarxigaDapagliflozin Propanediol	28	$37,153
Tresiba Flextouch U-100Insulin Degludec	33	$25,780
Tresiba Flextouch U-200Insulin Degludec	24	$18,995
TradjentaLinagliptin	19	$18,385
JanuviaSitagliptin Phosphate	12	$17,984
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog	12	$12,527
Humalog Kwikpen U-100Insulin Lispro	30	$11,800
SynthroidLevothyroxine Sodium	157	$11,772
Novolog FlexpenInsulin Aspart	37	$10,595

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy	$712	$568,416306 claims
Sanofi-aventis U.S. LLCLantus	$21	$2,42525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 952 endocrinology, diabetes & metabolism providers in California.

Other endocrinology, diabetes & metabolism in Ventura

Ronald ChochinovVentura$2.8M
Jerrold OlefskySan Diego$26.5M
Mark ChristiansenWalnut Creek$22.9M
Timothy BaileyEscondido$22.3M
Stanley HsiaLos Angeles$19.8M
Juan FriasSan Diego$14.1M
Paul NorwoodFresno$6.2M
Athena Philis-Tsimikasla Jolla$6M
David AhnNewport Beach$5.8M
Shlomo MelmedLos Angeles$3.3M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →